Acuta Capital Partners’s Crescent Biopharma CBIO Stock Holding History

Acuta Capital Partners’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-275	Closed	-$41.3K	–	46
2023 Q3	$41.3K	Buy	+275	New	+$43.4K	0.03%	45

Other funds holding CBIO

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Acuta Capital Partners's CBIO Position: Q4 2023 in Review

Acuta Capital Partners sold out of Crescent Biopharma (CBIO) in Q4 2023, closing a stake of 275 shares — an estimated $41.3K sold.

Acuta Capital Partners first reported a position in CBIO in Q3 2023 and held it in 1 quarter. The position peaked at $41.3K in Q3 2023. 58 funds tracked by Wall St. Rank hold CBIO as of Q4 2023.

Acuta Capital Partners reported no remaining Crescent Biopharma position as of Q4 2023 after selling out during the quarter.
Acuta Capital Partners sold 275 Crescent Biopharma shares in Q4 2023, an estimated $41.3K.
Acuta Capital Partners first reported a position in Crescent Biopharma in Q3 2023 and held it in 1 quarter.
Acuta Capital Partners's Crescent Biopharma position peaked at $41.3K in Q3 2023.
58 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2023.

Based on Acuta Capital Partners's 13F filing for Q4 2023, filed 14 Feb 2024.